Clinical Trials Logo

Recurrent Ovarian Cancer clinical trials

View clinical trials related to Recurrent Ovarian Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02117817 Withdrawn - Ovarian Cancer Clinical Trials

Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer

Start date: February 2015
Phase: Phase 1
Study type: Interventional

The purpose of the first part of this study or the dose escalation portion of the study is to determine what dose of BKM120 and Abraxane is safe to give when the two drugs are used at the same time in patients who are diagnosed with a solid cancer. A solid cancer is a cancer that does not involve the blood, bone marrow or lymph nodes. Dose escalation determines the least toxic and most effect dose of this drug combination for treatment. Once this dose is established, it will be used for the dose expansion phase of the study where we will determine the effect of BKM120 and Abraxane in women diagnosed with a recurrent endometrial or ovarian cancer. We will see whether the combination of both drugs improves the response and survival of patients treated on the two drug regimen. Also we will try to find out whether there are changes in tumors that can help us determine what patients are more likely to respond to BKM120 and Abraxane.

NCT ID: NCT02083536 Withdrawn - Ovarian Cancer Clinical Trials

LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma

Start date: May 2014
Phase: Phase 1
Study type: Interventional

The ultimate clinical aim of this proposed phase I trial is to evaluate the toxicity and determine the recommended phase II dose of combining the effect of LDFWART following administration of docetaxel for 6 cycles in patients with recurrent platinum-resistant ovarian cancer.